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Servicio de Microbiología, Hospital Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spaina; Clinical Microbiology Institute,
Wilsonville, Oregon, USAb; Central Manchester University Hospitals NHS Foundation Trust, Manchester Royal Infirmary, Manchester, United Kingdomc; Department of
Pathology & Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USAd; Division of Infectious Diseases,
Wayne State University School of Medicine, Detroit, Michigan, USAe; Department of Pathology, New York Medical College and Department of Pathology and Clinical
Laboratories, Westchester Medical Center, Valhalla, New York, USAf
Rapid identification of patients who are colonized with carbapenemase-producing organisms (CPO) is included in multiple na-
tional guidelines for containment of these organisms. In a multisite study, we evaluated the performance of the Cepheid Xpert
Carba-R assay, a qualitative diagnostic test that was designed for the rapid detection and differentiation of the blaKPC, blaNDM,
blaVIM, blaOXA-48, and blaIMP-1 genes from rectal swab specimens. A double rectal swab set was collected from 383 patients admit-
ted at four institutions (2 in the United States, 1 in the United Kingdom, 1 in Spain). One swab was used for reference culture
(MacConkey broth containing 1 mg/liter of meropenem and subcultured to aMacConkey agar plate with a 10-g meropenem
disk) and for sequencing of DNA obtained from carbapenem-nonsusceptible isolates for carbapenemase identification. The
other swab was used for the Xpert Carba-R assay. In addition to the clinical rectal swabs, 250 contrived specimens (108 well-
characterized CPO and 142 negative controls spiked onto negative rectal swabs) were tested. Overall, 149/633 (23.5%) samples
were positive by the Xpert Carba-R assay. In 6 samples, multiple targets were detected (4 VIM/OXA-48, 1 IMP-1/NDM, and 1
NDM/KPC). The Xpert Carba-R assay detected 155 targets (26 IMP-1, 30 VIM, 27 NDM, 33 KPC, 39 OXA-48) within a time
range of 32 to 48 min. The sensitivity, specificity, and positive and negative predictive values of the Xpert Carba-R assay com-
pared to those of the reference culture and sequencing results were 96.6% (95% confidence interval [CI], 92.2% to 98.9%), 98.6%
(95%CI, 97.1% to 99.4%), 95.3%, and 99.0%, respectively. The Cepheid Xpert Carba-R assay is an accurate and rapid test to
identify rectal colonization with CPO, which can guide infection control programs to limit the spread of these organisms.
The global spread of carbapenemase-producing organisms(CPO) has been highlighted by international health authori-
ties as a critical public health concern (1–3). Containment of this
spread, currently recommended in North American and Euro-
pean infection control guidelines, includes accurate and rapid
identification of colonization with CPO (4, 5). Different methods
for detection of CPO in rectal swabs have been used, including
culture with specific chromogenic media and in-house and com-
mercial molecular tests (6, 7). Culture-based methods are limited
by sensitivity and specificity issues depending on the composition
of the medium and the targeted carbapenemases (e.g., KPC, VIM,
NDM, IMP, or OXA-48 enzymes), the requirement of 24 to 48 h
for growth, and the need for confirmation with phenotypic and/or
molecular methods. Moreover, as the accuracy of culture methods
is highly dependent on medium formulation (type and concen-
tration of antibiotic supplementation), the increasing diversity of
carbapenemase enzymes and their variable expression affect the
sensitivity of culture methods (8, 9). In addition, bacterial load in
rectal or perirectal swabs also impacts the accuracy of culture-
based tests. For these reasons, molecular tests have been developed
and claim to overcome most of these limitations. These molecular
assays comprise multiplex-PCR-based assays (10, 11), isothermal
amplification (LAMP)-based assays (12), and microarray-based
assays (13, 14). Some of these assays have been evaluated using
only a collection of well-characterized CPO but not with clinical
samples and/or with a multisite approach.
In a previous study, we evaluated the sensitivity and specificity
of a PCR-based method in a cartridge format (Xpert MDRO as-
say) for detecting carbapenemase genes in rectal and perirectal
swabs run on the GeneXpert platform (Cepheid, Sunnyvale, CA).
Testing was performed in parallel with a reference culture method
(15). This molecular assay included targets for blaKPC, blaNDM,
and blaVIM genes but not for blaOXA-48 and blaIMP-1. In the current
study, an updated version of the Xpert Carba-R (Cepheid, Sunny-
vale, CA) was evaluated, which included all five gene targets. The
evaluation was performed in a multisite prospective study for Eu-
ropean marketing authorization under the European directive on
in vitro diagnostic medical devices (16).
MATERIALS AND METHODS
Study design, prospective, and contrived specimens.The study was con-
ducted between July 2013 and February 2014 at two institutions in the
United States (David Geffen School of Medicine, University of California,
Los Angeles, CA and Westchester Medical Center, Valhalla, NY) and two
institutions in Europe (Central Manchester University Hospitals NHS
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Foundation Trust, Manchester, United Kingdom and Hospital Ramón y
Cajal, Madrid, Spain). Specimens included prospectively recovered rectal
swabs (n 383) from patients who provided informed consent to partic-
ipate in the study or whose routine care included screening for CPO fol-
lowing local infection control policies. The protocol was approved by each
institution’s Ethics Committee. A double swab set (Venturi Transystem;
Copan, CA) and transport medium (liquid Stuart transport swab; Copan)
were used to collect and transport rectal swab specimens from eligible
subjects. One swab was used for reference culture, susceptibility testing,
and sequencing, and another swab was used for the Xpert Carba-R. To
diminish the potential bias of sampling differences, the two swabs were
gently rolled against one another before starting the Cepheid Xpert
Carba-R assay and culture procedure.
Due to the low prevalence of organisms containing some of the car-
bapenemase genes, the prospectively collected clinical rectal swab speci-
mens were supplemented with an additional 250 contrived specimens. To
prepare the contrived specimens, unique, well-characterized carbapen-
emase-producing (n 108) and non-carbapenemase-producing isolates
(n 142) were spiked into the negative rectal swab matrix (Table 1). Fifty
percent of the specimens were prepared at concentrations near the ana-
lytical limit of detection (LOD) of the Xpert Carba-R assay (ranging from
1.1 102 to 1.2 103 CFU/swab depending on the carbapenemase gene),
and the remaining specimens covered clinically relevant analyte concen-
trations (1, 3, and 10 LOD) (17). Isolates were seeded onto mock
rectal swabs that were prepared by dipping swabs into an individual stool
matrix that tested negative for carbapenemase genes. Nonseeded swabs
that were dipped into individual stool matrix were prepared as controls.
Results from the Xpert Carba-R assay for the clinical and contrived
specimens were compared to those of the reference culture and sequenc-
ing results.
Reference culture, susceptibility testing, and sequencing. One of the
prospectively collected rectal specimen swabs was placed in 10 ml of Mac-
Conkey broth (General Laboratory Products, Yorkville, IL, USA) contain-
ing a 10-g meropenem disk (BD, Franklin Lakes, NJ, USA) and was
vortexed. After 20 to 24 h of incubation at 35°C, MacConkey broths were
sent from the collecting sites to a central reference laboratory (Clinical
Microbiology Institute, OR, USA) for further processing. Upon receipt at
the central reference laboratory, an aliquot of 100-l was removed from
the MacConkey broth and inoculated onto a MacConkey agar plate after
which a 10-g meropenem disk was placed in the center of the plate.
Colonies on the MacConkey agar plate that grew within 27 mm of the
meropenem disk after an overnight incubation at 35°C were further tested
for the presence of a carbapenemase, as described by Lolans et al. (18) with
some modifications. Meropenem was used instead of ertapenem to im-
prove the specificities for Pseudomonas spp. and Acinetobacter spp., which
are intrinsically resistant to ertapenem. Colonies were also tested by a
standard disk diffusion method, and those classified as carbapenem-non-
susceptible (i.e., intermediate or resistant to ertapenem, imipenem, or
meropenem using the Clinical and Laboratory Standards Institute [CLSI]
interpretive criteria [19]) were subjected to bidirectional DNA sequence
analyses for the identification of the blaKPC, blaNDM, blaOXA-48, blaIMP-1,
and blaVIM genes. The bidirectional DNA sequence analyses were per-
formed at an independent laboratory (ACGT Inc., Wheeling, IL, USA)
using primers that were different from those used in the Xpert Carba-R
assay.
All contrived swab specimens were processed at the central reference
laboratory in the same manner as the clinical rectal swab specimens. They
were inoculated into MacConkey broth with a meropenem disk and sub-
sequently subcultured to MacConkey agar. Isolated colonies were tested
for susceptibility.
A positive reference culture result for both clinical and contrived spec-
imens was defined as the isolation of a carbapenem-nonsusceptible organ-
ism that contained a blaKPC, blaNDM, blaOXA-48, blaIMP-1, and/or blaVIM
gene confirmed by DNA sequence analysis. A negative reference culture
result was defined as either a reference culture that did not yield any
carbapenem-nonsusceptible organisms or the isolation of a carbapenem-
nonsusceptible organism that did not contain any of the target carbapen-
emase genes by DNA sequence analysis.
To minimize bias in specimen analyses, the laboratory personnel per-
forming the reference culture and DNA sequencing were not aware of the
Xpert Carba-R assay results.
Xpert Carba-R assay. Xpert Carba-R assay testing was performed us-
ing the second swab from the double swab set with the GeneXpert plat-
form. Testing was performed at the laboratories in each of the 4 partici-
pating institutions according to the manufacturer’s recommendations
and as previously described (15) within 24 to 48 h from collection. The
assay has a run time of47 min in the instrument. Quality control for the
Xpert Carba-R assays consisted of one positive and one negative control.
The former was composed of an Escherichia coli isolate containing a plas-
mid that included DNA fragments of all five target gene sequences, and
the latter was the same E. coli isolate with the cloning vector but without
the cloned fragments. The controls (product M219) were produced by
Maine Molecular Quality Controls, Inc. (http://www.mmqci.com/qc
-m219.php). The two controls were run on each day that specimens were
tested. Study specimens were not tested until correct results were obtained
for the negative and positive controls.
All contrived swab specimens were tested with the Xpert Carba-R
assay in the same manner as the clinical rectal swab specimens.
Data analysis, discrepant results, and statistics. The Xpert Carba-R
assay results were compared with reference culture and DNA sequencing
results. An Xpert Carba-R-positive result was considered when the Xpert
Carba-R assay detected the presence of at least one carbapenemase gene.
For each specimen, results for each of the five carbapenemase target genes
included in the Xpert Carba-R assay were reported separately, and these
were compared to results for the five carbapenemase target genes obtained
from reference culture and DNA sequencing.
A discrepant result was defined as a result obtained with the Xpert
Carba-R assay that did not correlate with the results of reference culture
and DNA sequencing of the same specimen. Discrepant testing was per-
formed for only those specimens that were positive for a target gene by the
Xpert Carba-R assay but did not show growth of colonies by culture. DNA
was extracted from the MacConkey broth (100 l) using the Qiagen
DNeasy blood and tissue kit using the protocol for Gram-negative bacte-
ria and amplified by PCR using primers corresponding to the targets that
were positive by the Xpert Carba-R assay results. If one of the five targets
was identified, bidirectional DNA sequence analysis was performed. A
positive result was considered a true positive for discrepant resolution by
the reference method in the analysis.
Discrepant testing was not performed for specimens that were nega-
tive for all target genes by the Xpert Carba-R assay but showed growth of
TABLE 1 Xpert Carba-R assay results by target for clinical and
contrived specimens
Xpert Carba-R assay
result
Clinical
specimens
(n 383)
Contrived
specimens
(n 250)
All
specimens
(n 633)
Positive (single and/or
combined targets)
42 107 149
IMP-1 0 25 25
VIM 2 24 26
NDM 2 23 25
KPC 13 19 32
OXA-48 20 15 35
VIM OXA-48 4 0 4
NDM KPC 1 0 1
IMP-1 NDM 0 1 1
Negative 341 143 484
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colonies on the MacConkey agar plate and from which one of the five
target genes was identified through DNA sequence analysis.
Sensitivity, specificity, and positive (PPV) and negative (NPV) predic-
tive values were also calculated for each target carbapenemase gene (20).
Statistical analysis was performed using 95% confidence intervals
(CIs) calculated with the Clopper-Pearson/Fisher exact CI (21) using
Minitab version 16 (Minitab, State College, PA). Values for the Kappa
coefficient, which gives a measure of the percentage of agreement between
the Xpert Carba-R assay and the reference method (after resolution of
discrepant results) beyond that expected by chance, were also calculated
(22).
RESULTS
Xpert Carba-R assay results with prospective rectal and con-
trived swab specimens. A total of 633 samples (383 clinical rectal
swabs and 250 contrived specimens) were included. Overall, 149/
633 (23.5%) samples were positive by the Xpert Carba-R assay,
and 484/633 (76.5%) were negative. The Xpert Carba-R assay am-
plified 155 positive targets (26 blaIMP-1, 30 blaVIM, 27 blaNDM, 33
blaKPC, 39 blaOXA-48). In 6 samples, multiple targets were detected
(4 blaVIM-blaOXA-48, 1 blaIMP-1-blaNDM, 1 blaNDM-blaKPC). Xpert
Carba-R results stratified by clinical and contrived specimen type
are shown in Table 1. Data analyses included discrepant resolution
results (see below). All positive results were obtained within 32 to
48 min.
Comparison of the Xpert Carba-R assay with the reference
method. Results from the Xpert Carba-R assay by individual tar-
get compared to the reference method (culture plus sequencing)
for all specimens are shown in Table 2. There were a total of 633
specimens, each with results for five individual targets for a total of
3,165 results. Specimens that were negative by both the Xpert
Carba-R assay and the reference method (3,004 total) were strat-
ified as follows: 606 for IMP-1, 601 for VIM, 606 for NDM, 599 for
KPC, and 592 for OXA-48.
Table 3 shows the overall performance of Xpert Carba-R com-
pared with that of the reference method. The results were defined
as positive for the Xpert Carba-R assay if any of the carbapen-
emase targets were positive, and they were defined as negative for
the Xpert Carba-R assay if all of the carbapenemase targets were
negative. On the combined set of clinical and contrived speci-
mens, sensitivity, specificity, PPV, and NPV were 96.6% (95% CI,
92.2% to 98.9%), 98.6% (95% CI, 97.1% to 99.4%), 95.3%, and
99.0%, respectively. The Kappa index for this comparison was
0.933 (0.900 to 0.967).
The performance of the Xpert Carba-R assay for different
targets, including CI, is shown in Table 4. Results included in
Tables 2 to 4 were also analyzed when discrepant results were
resolved (see below).
Discrepant results and resolution. Six specimens (4 prospec-
tive and 2 contrived specimens) were negative for all target genes
by Xpert Carba-R assay but were positive by the reference method
(culture and DNA sequencing) and were considered to be false
negatives. Bidirectional DNA sequence analysis identified 1
blaIMP-1, 2 blaVIM, 1 blaKPC, and 2 blaOXA-48 genes (Table 2). In
addition, 18 specimens (15 prospective and 3 contrived speci-
mens) were positive for at least one target gene by the Xpert
Carba-R assay and were negative by the reference method (Table
5). Eleven of the 18 specimens were considered to be true positives
after discrepant analyses, which included direct PCR analysis and
sequencing from the MacConkey broth. Of these 11 specimens,
there were 5 out of the 6 specimens in which multiple carbapen-
emase targets were detected by Xpert Carba-R assay. The remain-
ing 7 specimens were considered to be false positives, as no PCR
amplification was obtained from testing the MacConkey broth
(Table 5). Targets detected by Xpert Carba-R assay were 4 KPC
and one each of NDM, VIM, and OXA-48. In all of these cases,
positive results were fairly late (threshold cycles [CTs] ranged from
26.2 to 28.2 for KPCs and were31 for the remaining carbapen-
emases).
DISCUSSION
Detection of fecal carriers of CPO has become a routine clinical
practice in many parts of the world and is recommended by public
health organizations for the containment of the spread of these
isolates (3, 23). Different approaches are used in different coun-
tries and institutions, with some culturing rectal swabs on chro-
mogenic media. More recently, molecular approaches have been
developed to increase detection sensitivity and decrease reporting
time (7, 24). We evaluated, through a prospective multisite study,
the Cepheid Xpert Carba-R assay, a PCR-based method in a
cartridge format developed for detecting carbapenemase genes
in rectal swabs and run on the GeneXpert platform. This assay
TABLE 2 Results from the Xpert Carba-R assay and the reference
method (culture plus sequencing) by individual target for combined
clinical and contrived specimens
Xpert Carba-R
assay
Reference method (culture plus sequencing)
IMP-1 VIM NDM KPC OXA-48 Negative Total
IMP-1 26 0 0 0 0 0 26
VIM 0 29 0 0 0 1 30
NDM 0 0 26 0 0 1 27
KPC 0 0 0 29 0 4 33
OXA-48 0 0 0 0 38 1 39
Negative 1 2 0 1 2 3,004 3,010
Total 27 31 26 30 40 3,011 3,165
TABLE 3 Overall Xpert Carba-R performance versus that of the
reference method (culture plus sequencing) for combined clinical and
contrived specimens
Xpert Carba-R assay
Reference method (culture plus sequencing)
No. positive No. negative Total No.
Positive 142 7 149
Negative 6 478 484
Total 148 485 633
TABLE 4 Summary of Xpert Carba-R performance for different
carbapenemase targets versus that of the reference method (culture plus
sequencing) for combined clinical and contrived specimens
Target
gene
Sensitivity
(% [95% CI])
Specificity
(% [95% CI]) PPV (%) NPV (%)
IMP-1 96.3 (81.0–99.9) 100 (99.4–100) 100 99.8
VIM 93.5 (78.6–99.2) 99.8 (99.1–100) 96.7 99.7
NDM 100 (86.8–100) 99.8 (99.1–100) 96.3 100
KPC 96.7 (82.8–99.9) 99.3 (98.3–99.8) 87.9 99.8
OXA-48 95.0 (83.1–99.4) 99.8 (99.1–100) 97.4 99.7
Tato et al.
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was previously evaluated, but only three carbapenemase targets
(blaKPC, blaNDM, and blaVIM) were included (15). In the current
version, two additional targets were incorporated, blaOXA-48 and
blaIMP-1, to broaden the scope of the carbapenemases detected.
OXA-48 is increasingly recognized in most European countries,
predominating in most of the Mediterranean countries, whereas
IMP-1 is increasingly detected in Asia and Latin American coun-
tries (3, 25).
Overall, 633 specimens, including clinical rectal swabs and
contrived samples, were studied, yielding the potential detection
of 3,165 carbapenemase targets. Due to the absence or low preva-
lence of certain carbapenemase genes in organisms found in clin-
ical specimens, such as IMP-1, VIM, or NDM carbapenemases,
that reflects the local epidemiology of participating centers, con-
trived specimens were also included in the evaluation. This ap-
proach is normally used in molecular diagnostic platforms for in
vitro and clinical evaluations.
For our evaluation, the LODs of different carbapenemase tar-
gets were previously calculated (see Materials and Methods) (17).
Additionally, analytical reactivity (inclusivity) and potential
cross-reactivity (exclusivity) were also calculated, yielding 100%
detection of target-containing organisms and no cross-reactions
with other resistance genes, respectively (17). Moreover, it is no-
table that, in our evaluation, we used a highly sensitive method to
resolve potential discrepancies between the reference method
(culture plus DNA sequencing) and the Cepheid Xpert Carba-R
assay. This consisted of DNA extraction and sequencing from the
selective enrichment broth (MacConkey with a 10-g mero-
penem disk) inoculated with the original specimens. With this
approach, overall performance was excellent with sensitivity,
specificity, PPV, and NPV all higher than 95%. When perfor-
mance was evaluated separately for each carbapenemase, the per-
formance was best for IMP-1, and only sensitivities and positive
predictive values for VIM and KPC targets were lower than 95%.
Unlike other systems for direct detection of carbapenemase genes
in rectal swabs, we did not see high false-positive rates for metallo-
beta-lactamase targets (26).
Our multisite prospective evaluation was performed for the
initial European marketing authorization of the Xpert Carba-R
assay and was carried out under the European directive on in vitro
diagnostic medical devices (16). A limitation of our evaluation
was that the Xpert Carba-R assay included targets for widespread
carbapenemases at the time of the evaluation but did not include
some of the new emerging OXA-48 variants, such as OXA-181 and
OXA-232 carbapenemases. OXA-181 is one of the most prevalent
carbapenemases in South Africa and is increasingly recognized in
Asia and Europe (27–29), while OXA-232 is also increasingly de-
tected in Asia (30). Recent reports demonstrated that the Xpert
Carba-R version evaluated in our study was unable to detect these
two variants (31–33). Nevertheless, this was corrected in a novel
Xpert Carba-R version recently marketed, which accurately de-
tected these OXA-48 variants (34). The absence of detection of the
OXA-181 carbapenemase was also noted with other commercial
molecular assays that did not originally include this target. How-
ever, as in the Xpert Carba-R assay, subsequent modification of
the assay allowed detection of OXA-181 (34).
In our study, with the exception of 6 specimens (Table 2) in
which false-negative results were obtained, the Xpert Carba-R as-
say accurately detected all different targeted carbapenemase genes,
including those encoding the KPC, NDM, VIM, IMP-1, and
OXA-48 enzymes. The absence of detection in these 6 specimens
was not associated with a specific carbapenemase and may be as-
sociated with low bacterial load in the rectal swab specimens.
An additional advantage of the Cepheid Xpert Carba-R assay is
the ability to detect multiple resistance genes, an outcome not
previously reported in other evaluations (31). This occured in 6
TABLE 5 Discrepant testing resultsa
Sample
Reference method
Target(s) detected by
Xpert Carba-R assay
Discrepant analysis
Culture
Sequencing
of isolate
DNA extraction and sequencing
of MacConkey broth Outcomeb
A No isolate NAc IMP-1 IMP-1 TP
B Acinetobacter baumannii No bandsd KPC KPC TP
C Klebsiella pneumoniae OXA-48 OXA-48, VIM OXA-48, VIM TP
D No isolate NA OXA-48 OXA-48 TP
E Klebsiella pneumoniae OXA-48 OXA-48, VIM OXA-48, VIM TP
F No isolate NA VIM VIM TP
G No isolate NA KPC KPC TP
H No isolate NA OXA-48, VIM OXA-48, VIM TP
I No isolate NA OXA-48 OXA-48 TP
J Enterobacter cloacae KPC KPC, NDM KPC, NDM TP
K Klebsiella pneumoniae OXA-48 OXA-48, VIM OXA-48, VIM TP
L No isolate NA KPC No target gene FP
M No isolate NA NDM No target gene FP
N No isolate NA VIM No target gene FP
O No isolate NA KPC No target gene FP
P No isolate NA KPC No target gene FP
Q No isolate NA KPC No target gene FP
R No isolate NA OXA-48 No target gene FP
a True-positive and false-positive results are shown.
b TP, true positive; FP, false positive.
c NA, not applicable.
d No bands indicate that the sample did not meet PCR product band size inclusion criteria.
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cases (Tables 1 and 5). In 4 of them, the reference culture method
failed to detect this situation, but the genes were subsequently
detected by PCR and DNA sequencing from the MacConkey
broth. A potential explanation for these results may be that the
organisms recovered by reference culture are present in larger
amounts, which would limit the growth of the other organisms
present in a lower proportion, or because both carbapenemase-
bearing isolates were morphologically identical and one of them
was likely missed during the selection of the colonies.
However, a positive result with the Xpert Carba-R assay but
negative by culture may happen if the patient had been receiving
antibiotics, or the organism may carry a modified sequence of the
target gene, which was not expressed or was expressed at low
levels.
In conclusion, the Cepheid Xpert Carba-R assay is an accurate
technique for the detection of CPO in rectal swab specimens. This
assay allows rapid identification of patients colonized with CPO,
which can guide infection control programs designed to limit the
spread of these organisms in health care settings.
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